68Ga-PSMA PET/CT鉴别肾细胞癌脑转移与立体定向放疗后放射性坏死
本文报道一例43岁男性肾细胞癌患者,在接受立体定向放射外科治疗脑转移后,通过68Ga-PSMA PET/CT鉴别肿瘤进展与放射性坏死。作者强调68Ga-PSMA PET/CT在肾细胞癌患者放疗后随访中鉴别肿瘤进展与放射性坏死的潜在价值。
要点
- 肾细胞癌脑转移放疗后,CT和MRI鉴别放射性坏死与肿瘤进展具有挑战性。
- 68Ga-PSMA PET/CT可能有助于鉴别肾细胞癌放疗后肿瘤进展与放射性坏死。
- 本病例提示68Ga-PSMA PET/CT在肾细胞癌患者随访中具有潜在应用价值。
核心结论
- 68Ga-PSMA PET/CT在肾细胞癌患者立体定向放射外科治疗后鉴别肿瘤进展与放射性坏死方面具有潜在价值。
研究设计与样本
- 本文为个案报道,描述一例43岁男性肾细胞癌患者接受立体定向放射外科治疗脑转移后的影像鉴别过程。
主要发现
- 原文未报告具体的68Ga-PSMA PET/CT显像结果数值或定量参数。
- 作者通过该病例强调68Ga-PSMA PET/CT在肾细胞癌患者放疗后鉴别肿瘤进展与放射性坏死中的潜在价值。
临床怎么用
- 对于肾细胞癌脑转移接受立体定向放射外科治疗后的患者,可考虑应用68Ga-PSMA PET/CT辅助鉴别肿瘤进展与放射性坏死。
局限性
- 本文为单个病例报道,证据级别有限,尚需更多研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Renal cell carcinoma (RCC) is the most common primary malignancy of the kidney. Approximately 35% of patients of RCC presents with distant metastasis at initial evaluation. CT and MRI are the mainstay imaging modalities. Distinguishing radiation necrosis from tumor progression after stereotactic radiosurgery is challenging. Herein, we present a case of a 43-year-old man with RCC who was treated with stereotactic radiosurgery for brain metastases. We want to emphasize the potential value of 68Ga-PSMA PET/CT imaging in the differential diagnosis and follow-up of tumor progression from radiation necrosis in RCC patients.
引用
- Filizoglu N, Cetin IA, Kissa TN, et al. 68Ga-PSMA PET/CT to Distinguish Brain Metastasis of Renal Cell Carcinoma From Radiation Necrosis After Stereotactic Radiosurgery. Clin Nucl Med. 2021. PMID: 34284481. doi:10.1097/RLU.0000000000003820
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。